{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:18:30Z","timestamp":1794917910399,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836041018"],"award-info":[{"award-number":["836041018"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836041018"],"award-info":[{"award-number":["836041018"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836041018"],"award-info":[{"award-number":["836041018"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["836041018"],"award-info":[{"award-number":["836041018"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Adequate antibiotic dosing may improve outcomes in critically ill patients but is challenging due to altered and variable pharmacokinetics. To address this challenge, AutoKinetics was developed, a decision support system for bedside, real-time, data-driven and personalised antibiotic dosing. This study evaluates the feasibility, safety and efficacy of its clinical implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this two-centre randomised clinical trial, critically ill patients with sepsis or septic shock were randomised to AutoKinetics dosing or standard dosing for four antibiotics: vancomycin, ciprofloxacin, meropenem, and ceftriaxone. Adult patients with a confirmed or suspected infection and either lactate\u2009&gt;\u20092\u00a0mmol\/L or vasopressor requirement were eligible for inclusion. The primary outcome was pharmacokinetic target attainment in the first 24\u00a0h after randomisation. Clinical endpoints included mortality, ICU length of stay and incidence of acute kidney injury.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After inclusion of 252 patients, the study was stopped early due to the COVID-19 pandemic. In the ciprofloxacin intervention group, the primary outcome was obtained in 69% compared to 3% in the control group (OR 62.5, CI 11.4\u20131173.78, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, target attainment was faster (26\u00a0h, CI 18\u201342\u00a0h, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and better (65% increase, CI 49\u201384%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). For the other antibiotics, AutoKinetics dosing did not improve target attainment. Clinical endpoints were not significantly different. Importantly, higher dosing did not lead to increased mortality or renal failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In critically ill patients, personalised dosing was feasible, safe and significantly improved target attainment for ciprofloxacin.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: The trial was prospectively registered at Netherlands Trial Register (NTR), NL6501\/NTR6689 on 25 August 2017 and at the European Clinical Trials Database (EudraCT), 2017-002478-37 on 6 November 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-04098-7","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T13:04:55Z","timestamp":1662383095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock\u2014a two-centre randomised clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Luca F.","family":"Roggeveen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas M.","family":"Fleuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Thoral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier M.","family":"van Hest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron A. A.","family":"Mathot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora L.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm-Jan","family":"de Grooth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"van den Bogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand R. J.","family":"Girbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.","family":"Bosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W. G.","family":"Elbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"4098_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"key":"4098_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jama.2017.0131","volume":"317","author":"MD Howell","year":"2017","unstructured":"Howell MD, Davis AM. Management of sepsis and septic shock. JAMA. 2017;317:847\u20138.","journal-title":"JAMA"},{"key":"4098_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00134-018-5134-8","volume":"44","author":"H-J de Grooth","year":"2018","unstructured":"de Grooth H-J, Postema J, Loer SA, et al. Unexplained mortality differences between septic shock trials: a systematic analysis of population characteristics and control-group mortality rates. Intensive Care Med. 2018;44:311\u201322. https:\/\/doi.org\/10.1007\/s00134-018-5134-8.","journal-title":"Intensive Care Med"},{"key":"4098_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20:195\u2013203. https:\/\/doi.org\/10.1016\/j.molmed.2014.01.007.","journal-title":"Trends Mol Med"},{"key":"4098_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1164\/rccm.201609-1848OC","volume":"196","author":"VX Liu","year":"2017","unstructured":"Liu VX, Fielding-Singh V, Greene JD, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196:856\u201363. https:\/\/doi.org\/10.1164\/rccm.201609-1848OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4098_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1086\/379825","volume":"38","author":"RD MacArthur","year":"2004","unstructured":"MacArthur RD, Miller M, Albertson T, et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38:284\u20138. https:\/\/doi.org\/10.1086\/379825.","journal-title":"Clin Infect Dis"},{"key":"4098_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498\u2013509. https:\/\/doi.org\/10.1016\/S1473-3099(14)70036-2.","journal-title":"Lancet Infect Dis"},{"key":"4098_CR8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072\u201383. https:\/\/doi.org\/10.1093\/cid\/ciu027.","journal-title":"Clin Infect Dis"},{"key":"4098_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13054-019-2438-1","volume":"23","author":"LM Fleuren","year":"2019","unstructured":"Fleuren LM, Roggeveen LF, Guo T, et al. Clinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient: a cross-sectional study. Crit Care. 2019;23:185. https:\/\/doi.org\/10.1186\/s13054-019-2438-1.","journal-title":"Crit Care"},{"key":"4098_CR10","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1097\/CCM.0000000000000514","volume":"42","author":"TP Hanrahan","year":"2014","unstructured":"Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Crit Care Med. 2014;42:2527\u201336. https:\/\/doi.org\/10.1097\/CCM.0000000000000514.","journal-title":"Crit Care Med"},{"key":"4098_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-04059-1","volume":"9","author":"E Wistrand-Yuen","year":"2018","unstructured":"Wistrand-Yuen E, Knopp M, Hjort K, et al. Evolution of high-level resistance during low-level antibiotic exposure. Nat Commun. 2018;9:1\u201312. https:\/\/doi.org\/10.1038\/s41467-018-04059-1.","journal-title":"Nat Commun"},{"key":"4098_CR12","first-page":"497","volume":"81","author":"M Beumier","year":"2015","unstructured":"Beumier M, Casu GS, Hites M, et al. Elevated \u03b2-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497\u2013506.","journal-title":"Minerva Anestesiol"},{"key":"4098_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793\u20135. https:\/\/doi.org\/10.1056\/NEJMp1500523.","journal-title":"N Engl J Med"},{"key":"4098_CR14","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00134-018-5175-z","volume":"44","author":"CM Coopersmith","year":"2018","unstructured":"Coopersmith CM, De Backer D, Deutschman CS, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. 2018;44:1400\u201326. https:\/\/doi.org\/10.1007\/s00134-018-5175-z.","journal-title":"Intensive Care Med"},{"key":"4098_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00134-021-06549-1","volume":"47","author":"T De Corte","year":"2021","unstructured":"De Corte T, Elbers P, De Waele J. The future of antimicrobial dosing in the ICU: an opportunity for data science. Intensive Care Med. 2021;47:1481\u20133. https:\/\/doi.org\/10.1007\/s00134-021-06549-1.","journal-title":"Intensive Care Med"},{"key":"4098_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphar.2020.00646","volume":"11","author":"LF Roggeveen","year":"2020","unstructured":"Roggeveen LF, Guo T, Driessen RH, et al. Right dose, right now: development of autokinetics for real time model informed precision antibiotic dosing decision support at the bedside of critically ill patients. Front Pharmacol. 2020;11:646. https:\/\/doi.org\/10.3389\/fphar.2020.00646.","journal-title":"Front Pharmacol"},{"key":"4098_CR17","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s13063-019-3911-5","volume":"20","author":"LF Roggeveen","year":"2019","unstructured":"Roggeveen LF, Fleuren LM, Guo T, et al. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock\u2014rationale and design of a multicenter randomized controlled superiority trial. Trials. 2019;20:745. https:\/\/doi.org\/10.1186\/s13063-019-3911-5.","journal-title":"Trials"},{"key":"4098_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010. https:\/\/doi.org\/10.1136\/bmj.c869.","journal-title":"BMJ"},{"key":"4098_CR19","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/cc13874","volume":"18","author":"S Blot","year":"2014","unstructured":"Blot S, Koulenti D, Akova M, et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care. 2014;18:R99. https:\/\/doi.org\/10.1186\/cc13874.","journal-title":"Crit Care"},{"key":"4098_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcrc.2007.11.011","volume":"23","author":"ARH van Zanten","year":"2008","unstructured":"van Zanten ARH, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008;23:422\u201330. https:\/\/doi.org\/10.1016\/j.jcrc.2007.11.011.","journal-title":"J Crit Care"},{"key":"4098_CR21","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1002\/sim.3710","volume":"28","author":"B Han","year":"2009","unstructured":"Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. Stat Med. 2009;28:3329\u201346. https:\/\/doi.org\/10.1002\/sim.3710.","journal-title":"Stat Med"},{"key":"4098_CR22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/1745-6215-15-456","volume":"15","author":"BC Kahan","year":"2014","unstructured":"Kahan BC, Cro S, Dor\u00e9 CJ, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;15:456. https:\/\/doi.org\/10.1186\/1745-6215-15-456.","journal-title":"Trials"},{"key":"4098_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fpubh.2014.00145","volume":"2","author":"CA Michael","year":"2014","unstructured":"Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: causes, consequences, and management. Front Public Health. 2014;2:145. https:\/\/doi.org\/10.3389\/fpubh.2014.00145.","journal-title":"Front Public Health"},{"key":"4098_CR24","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. EUCAST Breakpoint tables for interpretation of MICs and zone diameters, version 8.0. (2018). https:\/\/www.eucast.org\/ast_of_bacteria\/previous_versions_of_documents\/. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf. Accessed 28 Jun 2021"},{"issue":"1","key":"4098_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13054-017-1609-1","volume":"21","author":"H-J de Grooth","year":"2017","unstructured":"de Grooth H-J, Geenen IL, Girbes AR, et al. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017;21(1):38. https:\/\/doi.org\/10.1186\/s13054-017-1609-1.","journal-title":"Crit Care."},{"key":"4098_CR26","doi-asserted-by":"publisher","first-page":"ofy313","DOI":"10.1093\/ofid\/ofy313","volume":"5","author":"Y Sakr","year":"2018","unstructured":"Sakr Y, Jaschinski U, Wittebole X, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit. Open Forum Infect Dis. 2018;5:ofy313. https:\/\/doi.org\/10.1093\/ofid\/ofy313.","journal-title":"Open Forum Infect Dis"},{"key":"4098_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9120920","author":"T Miyai","year":"2020","unstructured":"Miyai T, Imai S, Kashiwagi H, et al. A risk prediction flowchart of vancomycin-induced acute kidney injury to use when starting vancomycin administration: a multicenter retrospective study. Antibiotics. 2020. https:\/\/doi.org\/10.3390\/antibiotics9120920.","journal-title":"Antibiotics"},{"key":"4098_CR28","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW, Muller AE, Canton R, et al. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2018;73:564\u20138. https:\/\/doi.org\/10.1093\/jac\/dkx427.","journal-title":"J Antimicrob Chemother"},{"key":"4098_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bcp.12636","volume":"80","author":"M Schleibinger","year":"2015","unstructured":"Schleibinger M, Steinbach CL, Topper C, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharm. 2015;80:525\u201333.","journal-title":"Br J Clin Pharm."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04098-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04098-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T13:13:30Z","timestamp":1662383610000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04098-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4098"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04098-7","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"24 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the accredited Medical Ethics Review Committee (METC) of   Amsterdam UMC, location VUmc and the national Central Committee on Research Involving Human Subjects (CCMO) with protocol ID NL61682.029.1 and the study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice. Written informed consent was obtained from the patient or patient representative under the deferred consent procedure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"265"}}